194
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up

ORCID Icon, , , ORCID Icon, , , , , , , , , , , & show all
Pages 2689-2696 | Received 07 Sep 2018, Accepted 21 Mar 2019, Published online: 09 Apr 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Pavel Klener. (2020) Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. Expert Opinion on Therapeutic Targets 24:10, pages 1029-1045.
Read now

Articles from other publishers (4)

Aurélie Rondon, Jacques Rouanet & Françoise Degoul. (2021) Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials. Cancers 13:21, pages 5570.
Crossref
Mai Lin, Vincenzo Paolillo, Dao B. Le, Homer Macapinlac & Gregory C. Ravizzini. (2021) Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Current Problems in Cancer 45:5, pages 100796.
Crossref
Clifford M. Csizmar & Stephen M. Ansell. (2021) Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma. International Journal of Molecular Sciences 22:7, pages 3302.
Crossref
Karin Hohloch, Christine Windemuth-Kieselbach, Pier Luigi Zinzani, Roberto Cacchione, Wojciech Jurczak, C. Suh, Lorenz Trümper & Christian W. Scholz. (2020) Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. Annals of Hematology 99:5, pages 1073-1079.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.